Categories
- Active Surveillance
- Announcements
- Ask Dr. Barken
- Biomarker
- Biopsy
- Bone Metastases
- Brachytherapy
- Cancer Stem Cells
- Castration Resistant Prostate Cancer
- CETC
- Checklist
- Choline 11 PET Scan
- Clinical Trials
- Coaching
- Color Doppler Trans-Rectal Ultrasound
- Cryo Immunotherapy
- Cryoablation
- CTC
- Decision Making
- Diagnosis
- Exosome
- Ferumoxytol
- Focal Therapy
- Genome
- HIFU
- High Intensity Foucused Ultrasound
- Hormonal Blockade
- Hormone Refractory Disease
- Imaging
- Immune Therapy
- Intermittent Hormonal Blockade
- Journal Club
- Laser
- LIfe Style
- Liquid Biopsy
- Lymph Nodes
- Markers
- Metastatic Disease
- Metastatic Prostate Cancer Disease
- MRI
- MRI Guided Focal
- Multi Parameteric MRI
- Nutrition
- PCREF Support Group Meeting
- PET scans
- Photodynamic Therapy
- Prevention
- Prognosis
- Prostate Cancer
- PSA
- Radiation Therapy
- Radiation treatment
- Radical Prostatectomy
- Sequential Hormonal Blockade
- Sexual Dysfunction
- Support for Prosatate Cancer
- Survival prostate cancer
- Testosterone
- Theranostics
- Treatments for Prostate Cancer
- Tumor Spheres
- Uncategorized
- Vaccine
Category Archives: Hormonal Blockade
Prostate Cancer Convention 2014
Dr. Israel Barken, the medical director of the prostate cancer research and education foundation is interviewing Dr. Mark Scholz from the Prostate Cancer Research Institute about this year Prostate Cancer Convention.
Posted in Active Surveillance, Hormonal Blockade, Treatments for Prostate Cancer
Tagged Enzalutamide, Xtandi
2 Comments
Delaying Androgen Deprivation
Delaying Androgen Deprivation Therapy May not compromise Survival in Men with Prostate cancer and PSA-Only Relapse.
Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery.
Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery. Authors Sciarra A, et al. -Urol Oncol. 2013 Jul;31(5):607-14. Abstract presented and comments included by Dr. Israel Barken, the medical director of the … Continue reading
PSA Response to Neoadjuvant Androgen Deprivation Therapy iIs a Strong Predictor of Survival
PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era
Effect of Neoadjuvant Abiraterone Acetate plus Leuprolide Acetate in Localized HIgh Risk Prostate Cancer
Abiraterone and Lupron- Effect of Neoadjuvant Abiraterone Acetate plus Leuprolide Acetate in Localized HIgh Risk Prostate Cancer; Results of a Randomized Phase 2 Study.
Radical Prostatectomy – Radiation – Hormonal Blockade- What to do now?
Click here to view your video
Risk of Colorectal Cancer in Men with Prostate Cancer – Prevention is Key: Had a Colonoscopy Lately?- PatientPower Presentation
Study: Prostate cancer treatment linked to higher rate of colon cancer http://www2.med.umich.edu/prmc/media/newsroom/details.cfm?ID=1828 Article: Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer Jour Natl Cancer Institute Click here to view your video Prevention is Key: Had … Continue reading
Optimizing Sexual Function for Prostate Cancer Patients
Click here to view your video This week, watch the lecture by Dr. John Mulhall about Optimizing Sexual Function Outcomes for prostate cancer patients following treatment. The oral portion of this video presentation will be broadcast on Ask Dr. Barken Telephone … Continue reading
Depot Provera for Hot Flashes
Depot Provera for Hot Flashes